Sanofi to Invest 250 Million Euro for a Collaboration with Evotec

Related Vendors

TURCK GmbH

Glatt Ingenieurtechnik GmbH

Frewitt fabrique de machines SA

Offering of Joint Small-molecule Libraries

IIn a first-in class, ground-breaking 'open innovation initiative', both companies will combine their libraries and offer them for screening to Evotec's business partners. This creates one of the largest and most valuable sources of starting points for drug discovery with approx. 1,700,000 compounds available to screen.

The definitive agreement defines the conditions under which Evotec and Sanofi intend to jointly progress a portfolio of primarily oncology related projects, including five advanced, pre-clinical projects and further discovery-stage assets, to IND ("Investigational New Drug") status or other value inflection points before partnering them.

Statements

Dr Werner Lanthaler, Chief Executive Officer of Evotec: "We are very excited to welcome our new colleagues to Evotec. We would also like to welcome Sanofi as a new strategic customer and key alliance partner. This transaction supports our long-term strategic growth plans for our EVT Execute and EVT Innovate segments and brings significant value to Evotec's shareholders without the need for dilutive financing."

Dr. Elias Zerhouni, President Global R&D for Sanofi: "Sanofi is pleased to welcome Evotec as a new strategic partner in France. We highly value this collaboration, which will reinforce Toulouse Biopark as a major biomedical research platform in Europe and create a field of opportunities for our employees, while contributing to the vitality of the local ecosystem."

(ID:43271023)